Kim et al. [44] and Moreno et al. [18] suggest plerixafor treatment to cause internalization of myeloma and DLBCL cell surface-located CXCR4, respectively, as assessed by flow cytometry; whereas Fricker et al. [45] used flow cytometry-based assessment of anti-CXCR4 antibody binding as an indirect measure for binding of plerixafor to CXCR4. The gene discussed is CXCR4; the disease is plasma cell myeloma.